Showing 931-940 of 1784 results for "".
Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-Making
https://reachmd.com/programs/cme/partnering-with-patients-improving-first-line-treatment-selection-in-upper-gi-cancers-through-shared-decision-making/36579/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingPersonalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.Establishing Our Foundation of LGMD2I/R9: Unlocking the Genetics
https://reachmd.com/programs/cme/establishing-our-foundation-of-lgmd2ir9-unlocking-the-genetics/35877/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Breaking Barriers in AML: Risk Stratification, Molecular Profiling, and Novel Menin-Directed Treatment Options
https://reachmd.com/programs/cme/breaking-barriers-in-aml-risk-stratification-molecular-profiling-and-novel-menin-directed-treatment-options/33175/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Drug Shortages During the COVID-19 Pandemic
https://reachmd.com/programs/the-drug-report/drug-shortages-during-the-covid-19-pandemic/11440/Multiple sources are reporting shortages of drugs needed to help COVID-19 patients on medical ventilation. Here’s what’s being done in response.Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
https://reachmd.com/programs/cme/Beyond-Cognition-Managing-Alzheimers-as-an-Integrated-Neurodegenerative-Neuropsychiatric-Syndrome/54842/Examine integrated neurodegenerative and neuropsychiatric features of Alzheimer’s disease, including NPS biology and therapeutic strategies.Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1
https://reachmd.com/programs/cme/advances-in-treatment-of-hypoparathyroidism-importance-of-genetic-testing-for-autosomal-dominant-hypocalcemia-type-1/36097/Tune in to explore ADH type 1 care! Learn to recognize clinical features, enhance your diagnosis with genetic testing, and assess emerging therapies.Key Takeaways and Practice Integration
https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.Moving Beyond Lid Hygiene: Evidence-Based Treatment Strategies
https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/Join Drs. Devries and Koetting evaluate screening methods for accurate diagnosis of Demodex blepharitis and optimal treatment strategies for this condition.